MRTX Mirati Therapeutics, Inc.

4.05
+0.25  (7%)
Previous Close 3.80
Open 3.90
Price To book 0.96
Market Cap 101.00M
Shares 24,939,000
Volume 254,117
Short Ratio 8.88
Av. Daily Volume 160,547

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initial update due 2H 2017.
Sitravatinib plus nivolumab
Non-small cell lung cancer (NSCLC)
Phase 2 combination trial initiated June 2016. Update due mid-2017.
Mocetinostat and durvalumab
Non-small cell lung cancer (NSCLC)
Phase 2 initiated December 2015. Enrollment ongoing - update due 2H 2017.
Glesatinib (MGCD265)
Non-small cell lung cancer (NSCLC) patients with driver alterations in MET

Latest News

  1. Mirati Therapeutics To Present At The 2017 Jefferies Global Healthcare Conference
  2. Mirati reports 1Q loss
  3. Mirati Therapeutics Reports First Quarter 2017 Financial Results
  4. Mirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016
  5. Mirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference
  6. 5 Stocks Insiders Love Right Now
  7. Corporate Insiders at These 5 Companies Are Buying Large Sums of Stock
  8. Mirati Therapeutics Sets $65M Public Offering
  9. Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
  10. Mirati Therapeutics Announces Proposed Public Offering of Common Stock
  11. Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs
  12. How CardConnect Corp (CCN) Stacks Up Against Its Peers
  13. How Mirati Therapeutics (MRTX) Stock Stands Out in a Strong Industry
  14. Is Mirati Therapeutics, Inc. (MRTX) Going to Burn These Hedge Funds?
  15. Mirati Therapeutics, Inc. :MRTX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  16. Mirati Therapeutics Reports Financial Results And Provides Business Update For The Third Quarter 2016
  17. Mirati Therapeutics Appoints Chris LeMasters To Role Of Executive Vice President And Chief Business Officer
  18. 5 Stocks Under $10 That Could Make You a Lot of Money